# Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

> **NCT07392658** · PHASE2 · RECRUITING · sponsor: **Fondazione Ricerca Traslazionale** · enrollment: 33 (estimated)

## Conditions studied

- Metastatic NSCLC - Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Amivantamab

## Key facts

- **NCT ID:** NCT07392658
- **Lead sponsor:** Fondazione Ricerca Traslazionale
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392658, "Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07392658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*